It is Transgene's second most advanced neoantigen immunotherapy programme after TG4050 for head and neck cancer, which is in ...

Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.

双sgRNA系统具有精确和高效编辑的特性，报告RNA富集的RNP系统具有transgene-free、编辑效率高、细胞毒性低、脱靶效应低的特性。因此，利用RE-DSRNP制备 ...

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to ...

Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in the research and development of vaccines, oncology and new drug delivery technologies. Its portfolio of ...

Shares of French biotech Transgene (tumbled 13.5% to 1.01 euros by late morning after it announced that its randomized Phase ...

The controversies over regulation of GM crops, the technical ease of tracking, and the availability of grant funds has made transgene flow much easier to study, so it has achieved a higher profile.

Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to ...

Transgene announced that its randomized Phase II study to evaluate TG4001 in combination with avelumab versus avelumab alone in ...

Figure 1: Expression of reporter gene constructs derived from the gcy-5, lim-6 and lsy-6 genes. One potential explanation for our observations is that the vector backbone may dictate the packaging ...

A focus group is reviewing a new product and none of them believe it works. When asked for a testimonial, many in the group say the product is excellent.

21点评：今年5月，恒瑞医药曾公告显示，该PD-1联用方案上市申请遭到FDA拒绝，原因是生产相关的问题。根据公告，FDA需要全面评估企业在生产场地检查缺陷的完整答复，并且由于部分国家的旅行限制，FDA在审查周期内无法完成该项目必需的生物学研究监测计划 ...